PATRICIA
Clinical Trial Program
A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.
Phase II
Status
Recruiting
Tumour subtype:
HER2+
Scenario
Locally Advanced or Metastatic
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Eva M. Ciruelos Gil, MD, PhD (University Hospital 12 de Octubre, Madrid)
Sites
CONSORCIO HOSPITALARIO PROVINCIAL DE CASTELLON, HOSPITAL CLINIC DE BARCELONA, HOSPITAL CLÍNICO UNIV. LOZANO BLESA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL RAMON Y CAJAL, HOSPITAL SEVERO OCHOA DE LEGANÉS, HOSPITAL SON ESPASES, HOSPITAL SON LLATZER, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, HOSPITAL UNIVERSITARI SANT JOAN DE REUS, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO MADRID SANCHINARRO (CENTRO INTEGRAL ONCOLÓGICO CLARA CAMPAL (CIOCC)), HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, HU PUERTA DE HIERRO DE MAJADAHONDA, ICO GIRONA (HOSPITAL DR. JOSEP TRUETA), ICO HOSPITALET (DURAN I REYNALS)
